Cipla gets exclusive rights to market ophthalmic drug across 11 countries
APP13007 is a novel, patent protected and USFDA approved ophthalmic product.;
Taipei: Taiwan-based Formosa Pharmaceuticals has announced an exclusive licensing agreement with Cipla Limited for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007).
Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries such as India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, and Colombia.
APP13007 is a novel, patent protected and USFDA approved ophthalmic product. It offers a convenient twice-daily dosing regimen for 14 days without tapering, providing rapid and sustained relief from inflammation and pain. This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits.
"Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected global pharmaceutical brand. We appreciate their recognition and desire to add APP13007 to their rich portfolio of innovative medicines and look forward to working together to provide our novel therapy to ocular surgery patients to their audience." said Erick Co, President and CEO of Formosa Pharmaceuticals.
Read also: Cipla to invest ZAR 900 million in equity share capital of South Africa subsidiary
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.